In heart failure (HF) with reduced ejection fraction and sinus rhythm, heart rate reduction with ivabradine reduces the composite incidence of cardiovascular death and HF hospitalization. 
Introduction
Chronic heart failure (CHF) is a clinical syndrome frequently accompanied by a high load of co-morbidities and characterized by poor outcomes, despite the provision of optimal medical guideline-directed treatments. 1 In stable heart failure (HF) with reduced ejection fraction (HFrEF), it is not known whether the length of time from onset of signs or symptoms to full treatment initiation has an effect on clinical outcomes. Interestingly, mortality rates differ between acute de novo and acutely decompensated CHF patients. 2, 3 Cardiac resynchronization therapy (CRT) initiated early after emerging HF symptoms improved clinical outcomes more than it did when applied later after the development of clinical symptoms. 4 In patients requiring mechanical circulatory support, outcome was better in acute or sub-acute HF than in patients with worsening of CHF and longstanding symptoms. 5 Whether these associations also apply to patients with stable CHF of differing degrees of chronicity has not been thoroughly examined. High resting heart rates are related to poor outcomes in HFrEF in the general population, 6 in patients with high risk for vascular disease 7 and in stable HF. 8 Consistently, heart rate reduction decreased the composite outcome of cardiovascular death and hospitalization for HF in patients in sinus rhythm above a resting heart rate of 70 b.p.m., 9 and improved findings for all secondary endpoints including all-cause death and cardiovascular death in a population with heart rates of ≥75 b.p.m. 10 The present study addresses the two issues of whether the duration of HF symptoms influences outcomes and whether the treatment effect of heart rate reduction with ivabradine is modified by the duration of CHF.
Methods

Study design and participants
The SHIFT study [Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A 3-year randomized double-blind placebo-controlled international multicentre study; SHIFT (clinical trial registration: ISRCTN70429960)] was a randomized, double-blind, placebo-controlled clinical trial conducted in patients with moderate to severe HF and left ventricular (LV) dysfunction [LV ejection fraction (LVEF) of ≤35%] and diagnosed with HF ≥4 weeks prior to randomization. Patients were required to be in sinus rhythm, to be aged ≥18 years and to demonstrate a resting heart rate of ≥70 b.p.m. on two consecutive visits. Patients were assigned to either ivabradine or placebo. Ivabradine was started at 5 mg b.i.d. and adjusted according to heart rate achieved to either 7.5 mg b.i.d. or 2.5 mg b.i.d. SHIFT randomized patients on optimal guideline-directed medications at maximally tolerated doses for CHF, including beta-blockers. The design 5 and the main results 9,10 of the SHIFT trial have been published previously. The primary endpoint was a composite of cardiovascular death or hospital admission for worsening of HF. All endpoints were adjudicated by an independent endpoint committee. 9, 10 The SHIFT study showed that heart rate reduction with ivabradine reduced the composite of cardiovascular death and HF hospitalization and that the lowest incidences of events occurred when heart rate on treatment was <60 b.p.m. 
Follow-up and outcomes
The duration of HF symptoms was captured in the case report form for each patient by the investigators. Patients were categorized into groups according to HF duration at baseline by practical timeframes [≥4 weeks to <1.5 years (n = 2875), 1.5 years to <4 years (n = 1642) and ≥4 years (n = 1988)], which roughly represented tertiles of HFrEF duration. Baseline characteristics and treatments administered were reported for each group. The eight most common co-morbidities [chronic obstructive pulmonary disease (COPD), diabetes mellitus, anaemia, stroke, impaired renal function based on an 
Statistical analysis
Descriptive statistics are presented as means ± standard deviation (SD) for continuous variables, and as numbers and percentages for categorical variables. For baseline characteristics, the pooled placebo and ivabradine groups were divided into groups according to HF duration at baseline (≥4 weeks to <1.5 years; 1.5 years to <4 years; ≥4 years). Baseline characteristics were compared between groups established according to duration of HF using a Kruskal-Wallis test for continuous variables and a chi-squared test for categorical variables. The distributions of the numbers of co-morbidities in patients on each treatment arm according to duration of HF are also presented. The association between risk and disease duration was tested in a Cox proportional hazards model, with disease duration as a continuous variable (1-, 2-, 3-, 5-or 10-year increase), adjusted for prognostic factors at baseline [beta-blocker intake at randomization, heart rate, New York Heart Association (NYHA) class, LVEF, ischaemic aetiology, systolic blood pressure and eGFR], and hazard ratios (HRs), 95% confidence intervals (CIs) and P values were calculated. All time-to-first-event regression analyses were based on Cox proportional hazard models and HRs for ivabradine treatment relative to placebo were provided with 95% CIs and P-values calculated from the Wald statistics. The treatment effect of ivabradine vs. placebo was estimated in the duration of HF groups separately, from a Cox model adjusted for prognostic factors at baseline [beta-blocker intake at randomization, NYHA class (III or IV/II), LVEF, ischaemic HF (yes/no), age, systolic blood pressure, heart rate at baseline and creatinine eGFR]. Sensitivity analyses were also performed with other adjustments [age + co-morbidities (supplementary material online, Table S1 ]. P-values for interactions between randomized treatments and duration of HF groups were also provided by the addition of treatment by subgroup interaction to the model. The outcomes analysed were the primary endpoint (composite of cardiovascular death or hospital admission for worsening of HF), all-cause mortality and HF mortality. Time-to-event curves for each treatment arm according to duration of HF groups were estimated using the Kaplan-Meier method. SAS Version 9.2 (SAS Institute, Inc., Cary, NC, USA) was used for all statistical analyses.
Results
Baseline characteristics
In SHIFT, 6558 patients were randomized into the treatment arms (3268 ivabradine, 3290 placebo). Data on the duration of HF were available for 6505 patients. The baseline characteristics of all patients according to HF duration at baseline are depicted in Table 1 . The duration of HF was ≥4 weeks and <1.5 years in 2875 patients, from 1.5 years to <4 years in 1642 patients and ≥4 years in 1988 patients. Patients with longer HF duration tended to be older and to have a higher body mass index, a lower eGFR and higher systolic and diastolic blood pressure. Moreover, they were more likely to have a previous myocardial infarction, 
Co-morbidities
In order to investigate whether prevalences of single co-morbidities differed among patient groups stratified by duration of HF observed at baseline, the total co-morbidity load (i.e. numbers of co-morbidities) in these three groups was investigated. Figure 1 shows the distribution of numbers of co-morbidities by HF duration in the SHIFT population. In the group with short (<1.5 years; 1.5 years to <4 years; ≥4 years). Percentages were calculated for each class of disease duration. Mean ± standard deviation durations of HF in patients stratified according to number of co-morbidities were: no co-morbidities (n = 685): 2.33 ± 3.37 years; one co-morbidity (n = 1437): 2.95 ± 3.83 years; two co-morbidities (n = 2008): 3.72 ± 4.57 years; three co-morbidities (n = 1485): 3.87 ± 4.2 years; four or more co-morbidities (n = 890): 4.17 ± 4.38 years.
duration of HF, more patients had no or one co-morbidity than in the groups with HF of ≥1.5 years in duration. Findings of three or four co-morbidities were more frequent in patients with a HF duration of ≥4 years than in patients with HF of shorter duration. Figure 2 shows the effect of HF duration on the primary composite endpoint in patients treated with placebo or ivabradine. The event rate for the primary endpoint was significantly higher in patients with a longer rather than an intermediate or shorter duration of HF, irrespective of whether they were treated with placebo ( Figure 2A ) or ivabradine ( Figure 2B ) (log rank P < 0.0001). Similar results were observed for cardiovascular death (log rank P < 0.0001), regardless of whether patients were on placebo ( Figure 2C ) or ivabradine ( Figure 2D ). Similar results were obtained for worsening of HF (log rank P < 0.0001) in patients on either placebo ( Figure 2E ) or ivabradine ( Figure 2F ). To account for the high variability of disease duration, the associations were also evaluated in a statistical model with HF duration in a continuous manner. The treatment effects of ivabradine according to HF duration are summarized in Figure 4 . Hazard ratios with 95% CIs are adjusted for prognostic factors at baseline (beta-blocker intake at randomization, NYHA class, LVEF, ischaemic HF, age, systolic blood pressure, heart rate at baseline and creatinine clearance). There were significant reductions in occurrences of the primary composite endpoint and hospitalization for worsening of HF irrespective of HF duration. There were nominal decreases in cardiovascular mortality and all-cause mortality, which were not statistically significant, but a 40% decrease in HF mortality was observed in the subgroup of patients with HF duration of ≥4 years. The same analyses were performed with other adjustments. The effects of treatment were not affected by co-morbidities or risk indicators (Table S1 ). In order to exclude a threshold of HF duration for the effect of ivabradine, an adjusted Cox model on prognostic factors for the primary endpoint was performed using data for patients with a duration of HF of at least the threshold value, which varied from 0.5 years to 8 years. No threshold was detectable ( Figure 5 ). There was no significant heterogeneity of the treatment effects of ivabradine across the groups stratified by HF duration or across the defined endpoints. Neither the effect of HF duration on outcomes nor the effects of treatment were affected by co-morbidities or risk indicators ( Table S1 ). The drop in heart 
Outcomes
Primary outcome
Change in disease duration
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
P < 0.0001 P < 0.0001 
Discussion
This post hoc analysis of data from the SHIFT study demonstrates that duration of HF was associated with morbidity and mortality. Although higher chronicity of HF was accompanied by a higher prevalence of single cardiac and non-cardiac co-morbidities and a higher cumulative load of co-morbid conditions, poor outcome was independent of co-morbidities and risk indicators. The treatment effect of lowering heart rate with ivabradine was maintained across all groups with different durations of HF. The present paper reports a remarkable increase in all cardiovascular outcomes according to the duration of HF independent of co-morbidities and risk indicators. To the best of the present authors' knowledge, this is the first study to explore the impact of HF duration on outcomes in stable CHF. These data are in line with those reported in several studies on acute HF showing that mortality is higher in acute on chronic HF decompensation rather . Furthermore, patients who receive a mechanical circulatory support system earlier in the course of disease or CHF achieve better outcomes than those with longstanding CHF before implantation. 5 Finally, in patients with a shorter duration of CHF, a lower rate of cardiovascular death and HF hospitalization was observed after CRT device implantation than in patients with longstanding symptoms. 4 Recently, the ASCEND-HF investigators reported that patients with longer duration of HF presenting with acute decompensation had a higher rate of 180-day mortality.
11 The HRs lay between 1.82 and 2.02 for patients with HF durations ranging between 1-12 months and >60 months and were thus quite similar across the groups, indicating that there was no gradual worsening of outcomes. Similarly, patients with longer duration of HF appeared to be more difficult to stabilize as reflected by the finding of more persistent dyspnoea at 24 h.
11 Therefore, pathophysiological changes driven by acute decompensation may modify the relationship between risk and HF duration in the solely CHF patients described herein.
Chronic HF is a long-term condition accompanied by cardiovascular remodelling, which is progressive over time.
12 Therefore, it is likely that progressive maladaptive cardiac remodelling involving cardiac hypertrophy, defects in calcium handling and -adrenergic Figure 4 Effects of ivabradine treatment in different durations of heart failure (HF) indicated by hazard ratios (HR) with 95% confidence intervals (CI) for the primary endpoint, cardiovascular mortality, all-cause mortality and HF mortality according to duration of HF (<1.5 years, 1.5 years to <4 years, ≥4 years). a Numbers of patients in the placebo group by HF duration: <1.5 years, n = 1459; 1.5 to <4 years, n = 806; ≥4 years, n = 999. Numbers of patients in the ivabradine group by HF duration: <1.5 years, n = 1416; 1.5 to <4 years, n = 836; ≥4 years, n = 989. %PY, annual incidence rate. b Adjusted for prognostic factors [beta-blocker use at randomization, New York Heart Association class (II, III or IV), left ventricular ejection fraction (%), ischaemic HF (yes/no), age (years), systolic blood pressure (mmHg), heart rate (b.p.m.), creatinine clearance]. c P-value for interaction between randomized treatment and HF duration. d Composite of cardiovascular mortality and hospitalization for worsening HF. longer durations of symptoms were older and more commonly had previous myocardial infarctions, diabetes, stroke, atrial fibrillation, renal failure, COPD and peripheral artery disease. The association of HF duration with outcome remained robust after adjustments for co-morbidities or risk indicators. Co-morbidities were associated with higher rates of hospitalization and morbidity, 15 -17 which are, in turn, related to higher age. 18 Therefore, ageing, co-morbidities and factors directly acting on the pathophysiology of cardiac remodelling or impairing cardiac recovery in HF 12 may further contribute to higher event rates according to the chronicity of CHF. Finally, sub-clinical decompensations below the threshold for hospitalization in the outpatient setting may also be predictive, if not mechanistically involved, in death and hospitalization, as shown recently. 19 Patients with no or a remote decompensation, although having a somewhat lower risk, had a 22% incidence of cardiovascular death or HF-related hospitalization at follow-up in the PARADIGM trial, indicating that even in patients who achieve stability over a longer period, novel therapies should be introduced. 20 Heart rate predicts outcome in CHF 10 and decreasing heart rate reduces cardiovascular outcomes, as shown in the SHIFT trial. 9 The effect of heart rate reduction with ivabradine did not differ across the groups with different durations of HF. Heart rate reduction with ivabradine reduces the progressive remodelling of the left ventricle. 21 Relative risk reduction was similar across the groups with different durations of HF. This implies that a higher absolute Figure 6 Interaction of duration of heart failure (HF) with progressive maladaptive responses, impaired recovery and co-morbidities and consequently prognosis. Early administration of evidence-based treatments, including heart rate reduction, may significantly slow the course of deterioration. Arrows depict HF decompensation without optimal treatment (blue area) or optimal treatment (green area). Co-morbidities (red graph) and maladaptive remodelling (red shaded area) progress over time.
event rate reduction may be attainable in higher-risk groups with longer duration of HF. Therefore, the early introduction of HF therapies, as well as the timely introduction of cardiac resynchronization devices 4 or, in extremely severe HF, mechanical support systems, 5 may facilitate greater reductions in absolute event rates. In addition, the present findings show that the increase in risk associated with HF duration is independent of but is accompanied by increased co-morbidity loads. In many of these co-morbid conditions, heart rate also predicts risk, although an effect of heart rate reduction as in CHF has not yet been shown. However, recent findings suggest that the effects of ivabradine in patients with single co-morbidities such as impaired renal function, 22 COPD, 23 ageing 24 or a high cumulative co-morbidity load 17 are maintained. Low systolic blood pressure is an outcome predictor of HF, 25 particularly in association with high heart rate. 26 However, in the present study, blood pressure did not differ between patients with HF of longstanding duration and those with disease of a lower level of chronicity, which indicates that the age-associated increase in blood pressure overrides the HF-associated decreases in blood pressure. As heart rate is also associated with outcomes in conditions that are common co-morbidities in HF, such as COPD, critical care disease, cancer 27, 28 and endothelial function, 29 the unaffected efficacy of heart rate reduction is not surprising.
These findings may have implications for future trial designs. As patients with HF of long duration differ considerably from those with HF of shorter duration, it is surprising that this parameter is neither reported in the baseline characteristics of patients in HF trials nor is part of the randomization stratification. It could further be used to enrich HF populations towards higher event rates, although in the overall population this may limit the generalizability . Some limitations of this analysis should be acknowledged. This is a retrospective analysis and the treatment groups within the subgroups of patients stratified by HF duration were not subject to randomization. Therefore, this analysis is, by nature, hypothesis-generating. These data cannot address de novo or very recently diagnosed HF patients.
Conclusions
These results from the SHIFT study show that the duration of CHF independently predicts a poor outcome in patients with HF of long duration and may be related to longstanding remodelling and poorer capacity to recover, and de-remodelling of the failing heart. It is, however, accompanied by higher age and higher prevalences of non-cardiac and cardiac co-morbidities in these patients. This concept is summarized in Figure 6 . There is no sign of heterogeneity in the treatment effects of heart rate reduction with ivabradine according to HF duration. A medical history that shows a longer duration of HF is a risk indicator and should, therefore, be introduced into randomization strategies and risk evaluations in HF populations in future clinical trials.
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